Medication Summary
The goals of pharmacotherapy in osteoarthritis are to reduce morbidity and to prevent complications. Pay careful attention to a particular pharmacologic regimen's adverse-event profile.
Pharmacologic agents used in the treatment of osteoarthritis include the following:
- Corticosteroids
- Sodium hyaluronate
- Acetaminophen
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Muscle relaxants
- Glucocorticoids
Analgesics
Class Summary
Pain control is essential in the management of osteoarthritis. The goals of treatment include pain alleviation and improvement of functional status. Currently, no disease/structure-modifying intervention has been proven effective.
Acetaminophen (Tylenol, Panadol, Aspirin-Free Anacin)
An initial trial with acetaminophen (eg, Tylenol, Panadol, Aspirin-Free Anacin) is warranted in patients with mild to moderate symptoms from osteoarthritis who fail to get sufficient relief from nonpharmacologic measures. Acetaminophen is the drug of choice for patients who have a documented hypersensitivity to aspirin or NSAIDs, who have a history of upper GI disease, or who are on anticoagulants.
Duloxetine (Cymbalta)
Potent inhibitor of neuronal serotonin and norepinephrine reuptake. Indicated for chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.
Analgesic, Topical
Class Summary
Topical analgesics are used for osteoarthritis involving relatively superficial joints, such as the knee joint and the joints of the hands. These agents are much less effective for deeper joints, such as the hip joint.
Capsaicin (Dolorac, Capsin, Zostrix)
Capsaicin (Dolorac, Capsin, Zostrix) is a topical analgesic of choice in osteoarthritis. Derived from plants of the Solanaceae family, it may render skin and joints insensitive to pain by depleting substance P in peripheral sensory neurons. Capsaicin must be used for at least 2 weeks for the full effects to be appreciated. Topical analgesics are used for osteoarthritis involving relatively superficial joints, such as the knee joint and the joints of the hands. These agents are much less effective for deeper joints, such as the hip joint.
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Class Summary
These agents have analgesic, anti-inflammatory, and antipyretic activities. They are used to relieve osteoarthritis pain when the clinical response is unsatisfactory to acetaminophen. The mechanism of action is nonselective inhibition of COX-1 and -2, resulting in reduced synthesis of prostaglandins and thromboxanes. Other mechanisms may also exist, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.
In more inflammatory presentations of osteoarthritis, such as knee involvement with effusion, these agents may be used as first-line pharmacologic therapy.
Use the lowest effective dose or intermittent therapy if symptoms are intermittent.
Patients at high risk for GI toxicity may consider adding misoprostol or a proton pump inhibitor to the regimen or substituting a COX-2–specific inhibitor for the NSAID.
Naproxen (Aleve, Anaprox, Anaprox DS, Naprelan, Naprosyn)
For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis.
NSAIDs decrease intraglomerular pressure and decrease proteinuria.
Piroxicam (Feldene)
Decreases activity of cyclo-oxygenase, which in turn inhibits prostaglandin synthesis. These effects decrease formation of inflammatory mediators.
Ketoprofen (Orudis, Oruvail)
For relief of mild to moderate pain and inflammation. Small dosages are initially indicated in small and elderly patients and in those with renal or liver disease. Doses of more than 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response.
Ibuprofen (Ibuprin, Advil, Motrin)
Ibuprofen (eg, Ibuprin, Advil, Motrin) relieves pain and inflammation. It is widely available and is relatively inexpensive as a generic drug. After the very early stages of osteoarthritis, inflammation begins to play a role in the disease. Thus, medications with a combination of analgesic and anti-inflammatory properties become more desirable, at least in theory.
Meloxicam (Mobic)
To some extent, meloxicam (Mobic) is more selective for COX-2 receptors, compared with traditional NSAIDs. It decreases activity of cyclooxygenase, which in turn inhibits prostaglandin synthesis. These effects decrease formation of inflammatory mediators.
Diclofenac (Voltaren, Arthrotec, Cataflam)
Designated chemically as 2-[(2,6-dichlorophenyl) amino] benzeneacetic acid, monosodium salt, with an empirical formula of C14 H10 Cl2 NO2 NA. One of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. Believed to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins. Can cause hepatotoxicity; hence, liver enzymes should be monitored in the first 8 weeks of treatment.
Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation. Delayed-release, enteric-coated form is diclofenac sodium, and immediate release form is diclofenac potassium. Has relatively low risk for bleeding GI ulcers.
Esomeprazole and naproxen (Vimovo)
Naproxen component is indicated for relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Naproxen is an NSAID that inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis.
Esomeprazole component is indicated to decrease risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Esomeprazole is the S-isomer of omeprazole, a proton pump inhibitor. Inhibits gastric acid secretion by inhibiting H+/K+-ATPase enzyme system at secretory surface of gastric parietal cells.
COX-2 inhibitors
Class Summary
Although increased cost can be a negative factor, the incidence of costly and potentially fatal GI bleeds is less in nonaspirin users receiving COX-2 inhibitors than it is in patients using traditional NSAIDs.
Celecoxib (Celebrex)
Celecoxib (Celebrex) is a COX-2–specific inhibitor. At therapeutic concentrations, COX-2 (inducible by cytokines at sites of inflammation, such as the joints) is inhibited and COX-1 isoenzyme (present in platelets and GI tract) is spared; therefore, in nonaspirin users, incidence of GI toxicity, such as endoscopic peptic ulcers, bleeding ulcers, perforations, and obstructions, is decreased when compared with nonselective NSAIDs. COX-2 is expressed in the kidney; however, the renal safety profile is not significantly superior to that of NSAIDs.
Opioid Analgesics
Class Summary
These agents are used in patients whose pain has not been controlled with weaker analgesic medications. They are a particularly reasonable choice in patients who do not want joint replacement surgery, are too medically ill for joint replacement, are not candidates for joint replacement for other reasons, or are trying to buy time for subsequent joint-replacement surgery.
The results of a retrospective cohort study found that elderly patients (aged 65 y and older) with arthritis are more likely to incur a fracture when initiating opioids as opposed to NSAIDs (25 fractures per 1000 person-years; hazard ratio, 4.9; confidence interval, 3.5-6.9). Higher opioid dose was associated with greater risk of fracture. In addition, results showed that during the first 2 weeks of initiating opioid treatment, short-acting opioids are associated with a greater fracture risk than are long-acting opioids.[78]
Oxycodone (OxyContin, Roxicodone)
Pure narcotic analgesics, such as oxycodone, might be the initial DOC. Eventually, this short-acting narcotic can be switched to a long-acting transdermal preparation, such as fentanyl (Duragesic patch).
Tramadol (Ultram, Ultram ER)
Inhibits ascending pain pathways, altering perception of and response to pain. Also inhibits reuptake of norepinephrine and serotonin
Corticosteroids
Class Summary
Intra-articular pharmacologic therapy includes corticosteroid injection and viscosupplementation, which may provide pain relief and have an anti-inflammatory effect on the affected joint.[49, 50] Radiologists may aid in the treatment of osteoarthritis by administering image-guided intra-articular injections of steroids.
Steroid injections generally result in a clinically and statistically significant reduction in osteoarthritic knee pain as soon as 1 week after injection. The effect may last, on average, anywhere from 4-6 weeks per injection, but this benefit is unlikely to continue beyond that time frame.[51]
Methylprednisolone (Depo-Medrol, Medrol, Solu-Medrol)
Methylprednisolone decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Betamethasone (Celestone Soluspan)
Betamethasone decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. Its affects the production of lymphokines and has an inhibitory effect on the Langerhans cells.
Triamcinolone (Aristospan Intra-Articular)
Triamcinolone decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Sodium Hyaluronate Agents
Class Summary
These agents are used to treat pain in osteoarthritis of knee in patients not responding to conservative, nonpharmacologic therapy and simple analgesics (ie, acetaminophen).
Sodium Hyaluronate (Euflexxa, Hyalgan, Orthovisc, Supartz, Synvisc, Synvisc-One)
This is a hyaluronic acid derivative that supports the lubricating and shock-absorbing properties of articular cartilage.
Kirkley A, Birmingham TB, Litchfield RB, Giffin JR, Willits KR, Wong CJ, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. Sep 11 2008;359(11):1097-107. [Medline].
Kellgren JH. Osteoarthritis in patients and populations. Br Med J. 1961;Vol 2.:1-6.
Loughlin J. The genetic epidemiology of human primary osteoarthritis: current status. Expert Rev Mol Med. May 24 2005;7(9):1-12. [Medline].
Cheung EV, Adams R, Morrey BF. Primary osteoarthritis of the elbow: current treatment options. J Am Acad Orthop Surg. Feb 2008;16(2):77-87. [Medline].
Dagenais S, Garbedian S, Wai EK. Systematic review of the prevalence of radiographic primary hip osteoarthritis. Clin Orthop Relat Res. Mar 2009;467(3):623-37. [Medline]. [Full Text].
Lee P, Rooney PJ, Sturrock RD, Kennedy AC, Dick WC. The etiology and pathogenesis of osteoarthrosis: a review. Semin Arthritis Rheum. Spring 1974;3(3):189-218. [Medline].
Murray RO. The aetiology of primary osteoarthritis of the hip. Br J Radiol. Nov 1965;38(455):810-24. [Medline].
Radin ER, Paul IL, Rose RM. Pathogenesis of primary osteoarthritis. Lancet. Jun 24 1972;1(7765):1395-6. [Medline].
Sharma L. Epidemiology of osteoarthritis. In: Moskowitz RW, Howell DS, Altman, RD, et al, eds. Osteoarthritis. 3rd ed. 2001:3-27.
Veys E, Verbruggen G. Evolution and prognosis of osteoarthritis. In: Reginster JY, Pelletier JP, Martel-Pelletier J, et al, eds. Osteoarthritis. 1999:312-3.
Valderrabano V, Horisberger M, Russell I, Dougall H, Hintermann B. Etiology of ankle osteoarthritis. Clin Orthop Relat Res. Jul 2009;467(7):1800-6. [Medline]. [Full Text].
Buckland-Wright C, Verbruggen G, Haraoui PB. Imaging: radiological assessment of hand osteoarthritis. In: Osteoarthritis Cartilage. 2000:55-6.
Jewell FM, Watt I, Doherty M. Plain radiographic features of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, NY: Oxford University Press; 1998:217-37.
Mankin HJ. The reaction of articular cartilage to injury and osteoarthritis (first of two parts). N Engl J Med. Dec 12 1974;291(24):1285-92. [Medline].
Miller EJ, Van der Korst JK, Sokoloff L. Collagen of human articular and costal cartilage. Arthritis Rheum. Feb 1969;12(1):21-9. [Medline].
Phadke K. Regulation of metabolism of the chondrocytes in articular cartilage--an hypothesis. J Rheumatol. Dec 1983;10(6):852-60. [Medline].
Resnick D, Niwayama G. Degenerative disease of extraspinal locations. In: Resnick D, ed. Diagnosis of Bone and Joint Disorders. 3rd ed. 1995:1263-1371.
Poole AR. An introduction to the pathophysiology of osteoarthritis. Front Biosci. Oct 15 1999;4:D662-70. [Medline].
Radin EL, Paul IL. Response of joints to impact loading. I. In vitro wear. Arthritis Rheum. May-Jun 1971;14(3):356-62. [Medline].
Burkitt HG, Stevens A, Lowe JS. Skeletal system. In: Basic Histopathology. 3rd ed. New York, NY: Churchill Livingstone; 1996:260.
Hamerman D. The biology of osteoarthritis. N Engl J Med. May 18 1989;320(20):1322-30. [Medline].
Hartmann C, De Buyser J, Henry Y, Morère-Le Paven MC, Dyer TA, Rode A. Nuclear genes control changes in the organization of the mitochondrial genome in tissue cultures derived from immature embryos of wheat. Curr Genet. May 1992;21(6):515-20. [Medline].
Howell DS. Pathogenesis of osteoarthritis. Am J Med. Apr 28 1986;80(4B):24-8. [Medline].
Bullough PG. The geometry of diarthrodial joints, its physiologic maintenance, and the possible significance of age-related changes in geometry-to-load distribution and the development of osteoarthritis. Clin Orthop Relat Res. May 1981;61-6. [Medline].
Aigner T, Rose J, Martin J, Buckwalter J. Aging theories of primary osteoarthritis: from epidemiology to molecular biology. Rejuvenation Res. Summer 2004;7(2):134-45. [Medline].
OUTERBRIDGE RE. The etiology of chondromalacia patellae. J Bone Joint Surg Br. Nov 1961;43-B:752-7. [Medline].
Zgoda M, Paczek L, Bartlomiejczyk I, Sieminska J, Chmielewski D, Górecki A. Age-related decrease in the activity of collagenase in the femoral head in patients with hip osteoarthritis. Clin Rheumatol. Feb 2007;26(2):240-1. [Medline].
Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev. 1988;10:1-28. [Medline].
Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. Jul 1 1988;109(1):18-24. [Medline].
Goulston LM, Kiran A, Javaid MK, et al. Does obesity predict knee pain over fourteen years in women, independently of radiographic changes?. Arthritis Care Res (Hoboken). Oct 2011;63(10):1398-406. [Medline].
Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheum Dis Clin North Am. May 1999;25(2):283-98, vi. [Medline].
Felson DT. Risk factors for osteoarthritis: understanding joint vulnerability. Clin Orthop Relat Res. Oct 2004;S16-21. [Medline].
Hoaglund FT, Yau AC, Wong WL. Osteoarthritis of the hip and other joints in southern Chinese in Hong Kong. J Bone Joint Surg Am. Apr 1973;55(3):545-57. [Medline].
Roberts J, Burch TA. Osteoarthritis prevalence in adults by age, sex, race, and geographic area. Vital Health Stat 11. Jun 1966;1-27. [Medline].
Chapple CM, Nicholson H, Baxter GD, Abbott JH. Patient characteristics that predict progression of knee osteoarthritis: A systematic review of prognostic studies. Arthritis Care Res (Hoboken). Aug 2011;63(8):1115-25. [Medline].
[Guideline] Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. Nov 1990;33(11):1601-10. [Medline].
[Guideline] Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. May 1991;34(5):505-14. [Medline].
[Guideline] Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. Aug 1986;29(8):1039-49. [Medline].
Brandt KD. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers. J Rheumatol Suppl. Aug 1989;18:39-42. [Medline].
Recht MP, Kramer J, Marcelis S, Pathria MN, Trudell D, Haghighi P, et al. Abnormalities of articular cartilage in the knee: analysis of available MR techniques. Radiology. May 1993;187(2):473-8. [Medline].
Recht MP, Goodwin DW, Winalski CS, White LM. MRI of articular cartilage: revisiting current status and future directions. AJR Am J Roentgenol. Oct 2005;185(4):899-914. [Medline].
Jewell FM, Watt I, Doherty M. Plain radiographic features of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, NY: Oxford University Press; 1998:217-37.
Hunter DJ. Advanced imaging in osteoarthritis. Bull NYU Hosp Jt Dis. 2008;66(3):251-60. [Medline].
Keen HI, Wakefield RJ, Conaghan PG. A systematic review of ultrasonography in osteoarthritis. Ann Rheum Dis. May 2009;68(5):611-9. [Medline].
Kraus VB, McDaniel G, Worrell TW, Feng S, Vail TP, Varju G, et al. Association of bone scintigraphic abnormalities with knee malalignment and pain. Ann Rheum Dis. Nov 2009;68(11):1673-9. [Medline].
[Guideline] Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. Feb 2008;16(2):137-62. [Medline].
Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. Apr 1 1992;116(7):535-9. [Medline].
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. Sep 2000;43(9):1905-15. [Medline].
Neustadt DH. Intra-articular therapy. In: Moskowitz RW, Howell DS, Altman RD, et al, eds. Osteoarthritis. 3rd ed. 2001:393-409.
Lineker SC, Bell MJ, Boyle J, Badley EM, Flakstad L, Fleming J, et al. Implementing arthritis clinical practice guidelines in primary care. Med Teach. Mar 2009;31(3):230-7. [Medline].
Godwin M, Dawes M. Intra-articular steroid injections for painful knees. Systematic review with meta-analysis. Can Fam Physician. Feb 2004;50:241-8. [Medline]. [Full Text].
Lambert RG, Hutchings EJ, Grace MG, Jhangri GS, Conner-Spady B, Maksymowych WP. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. Jul 2007;56(7):2278-87. [Medline].
Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol. Feb 2007;47(1):78-83. [Medline].
Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol. Feb 2006;20(1):81-97. [Medline].
Perrot S, Poiraudeau S, Kabir M, Bertin P, Sichere P, Serrie A, et al. Active or passive pain coping strategies in hip and knee osteoarthritis? Results of a national survey of 4,719 patients in a primary care setting. Arthritis Rheum. Nov 15 2008;59(11):1555-62. [Medline].
Anandacoomarasamy A, Leibman S, Smith G, et al. Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage. Ann Rheum Dis. Jan 2012;71(1):26-32. [Medline].
McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol. Apr 1992;19(4):604-7. [Medline].
[Best Evidence] Jan MH, Lin CH, Lin YF, Lin JJ, Lin DH. Effects of weight-bearing versus nonweight-bearing exercise on function, walking speed, and position sense in participants with knee osteoarthritis: a randomized controlled trial. Arch Phys Med Rehabil. Jun 2009;90(6):897-904. [Medline].
[Best Evidence] Chaipinyo K, Karoonsupcharoen O. No difference between home-based strength training and home-based balance training on pain in patients with knee osteoarthritis: a randomised trial. Aust J Physiother. 2009;55(1):25-30. [Medline].
[Best Evidence] Wang C, Schmid CH, Hibberd PL, Kalish R, Roubenoff R, Rones R, et al. Tai Chi is effective in treating knee osteoarthritis: a randomized controlled trial. Arthritis Rheum. Nov 15 2009;61(11):1545-53. [Medline].
Marks R, Allegrante JP. Chronic osteoarthritis and adherence to exercise: a review of the literature. J Aging Phys Act. Oct 2005;13(4):434-60. [Medline].
Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. Mar 2005;13(3):216-24. [Medline].
Stitik TP, Levy JA. Viscosupplementation (biosupplementation) for osteoarthritis. Am J Phys Med Rehabil. Nov 2006;85(11 Suppl):S32-50. [Medline].
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. Apr 19 2006;CD005321. [Medline].
Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol. Nov 1998;25(11):2203-12. [Medline].
Stitik TP, Blacksin MF, Stiskal DM, Kim JH, Foye PM, Schoenherr L, et al. Efficacy and safety of hyaluronan treatment in combination therapy with home exercise for knee osteoarthritis pain. Arch Phys Med Rehabil. Feb 2007;88(2):135-41. [Medline].
Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. Dec 2007;465:241-8. [Medline].
Liu H, Abbott J, Bee JA. Pulsed electromagnetic fields influence hyaline cartilage extracellular matrix composition without affecting molecular structure. Osteoarthritis Cartilage. Mar 1996;4(1):63-76. [Medline].
Zizic TM, Hoffman KC, Holt PA, Hungerford DS, O'Dell JR, Jacobs MA, et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. J Rheumatol. Sep 1995;22(9):1757-61. [Medline].
Fukuda TY, Alves da Cunha R, Fukuda VO, et al. Pulsed shortwave treatment in women with knee osteoarthritis: a multicenter, randomized, placebo-controlled clinical trial. Phys Ther. Jul 2011;91(7):1009-17. [Medline].
Ying KN, While A. Pain relief in osteoarthritis and rheumatoid arthritis: TENS. Br J Community Nurs. Aug 2007;12(8):364-71. [Medline].
Selfe TK, Taylor AG. Acupuncture and osteoarthritis of the knee: a review of randomized, controlled trials. Fam Community Health. Jul-Sep 2008;31(3):247-54. [Medline]. [Full Text].
Marx RG. Arthroscopic Surgery for Osteoarthritis of the Knee?. New England Journal of Medicine. 2008;Vol. 359:1169-1170. [Full Text].
Barclay L, Nghiem HT. Arthroscopic Surgery May Not Be Helpful for Knee Osteoarthritis. Medscape. Available at http://www.medscape.com/viewarticle/580300. Accessed September 29, 2010.
Pagenstert G, Knupp M, Valderrabano V, Hintermann B. Realignment surgery for valgus ankle osteoarthritis. Oper Orthop Traumatol. Mar 2009;21(1):77-87. [Medline].
Daras M, Macaulay W. Total hip arthroplasty in young patients with osteoarthritis. Am J Orthop (Belle Mead NJ). Mar 2009;38(3):125-9. [Medline].
Kuo A, Ezzet KA, Patil S, Colwell CW Jr. Total hip arthroplasty in rapidly destructive osteoarthritis of the hip: a case series. HSS J. Sep 2009;5(2):117-9. [Medline]. [Full Text].
Miller M, Stürmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. Mar 2011;59(3):430-8. [Medline].
Belhorn LR, Hess EV. Erosive osteoarthritis. Semin Arthritis Rheum. Apr 1993;22(5):298-306. [Medline].
Kellgren JH, Moore R. Generalized osteoarthritis and Heberden's nodes. Br Med J. 1952;Vol 1:181-7.
Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology. Jun 2000;215(3):835-40. [Medline].

